Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Gut

• Publication date

  2014-11-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/gutjnl-2014-308163PMID 25398770
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2014cited by this paper
• Risk of stroke in long-term dialysis patients compared with the general population.

  2014cited by this paper
• Therapy of hepatitis C--back to the future.

  2014cited by this paper
• Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study.

  2014cited by this paper
• Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients

  2014cited by this paper
• Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database.

  2013cited by this paper
• Autoantibodies and Autoimmune Disease During Treatment of Children With Chronic Hepatitis C

  2013cited by this paper
• Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma

  2013cited by this paper
• Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.

  2012cited by this paper
• Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations

  2012cited by this paper
• Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study.

  2012cited by this paper
• Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis.

  2012cited by this paper
• Association of hepatitis C virus infection with risk of ESRD: a population-based study.

  2012cited by this paper
• Does Hepatitis C Virus Infection Increase Risk for Stroke? A Population-Based Cohort Study

  2012cited by this paper
• Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

  2012cited by this paper
• Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection.

  2012cited by this paper
• Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis.

  2012cited by this paper
• Validation of the national health insurance research database with ischemic stroke cases in Taiwan

  2011cited by this paper
• Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.

  2011cited by this paper
• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2011cited by this paper
• Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.

  2011cited by this paper
• Hepatitis C Virus Infection and Increased Risk of Cerebrovascular Disease

  2010cited by this paper
• Epidemiology of hepatitis B and C viruses: a global overview.

  2010cited by this paper
• Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.

  2010cited by this paper
• Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C

  2009cited by this paper
• Prevalence of hepatitis C serum antibody in autoimmune diseases.

  2009cited by this paper
• Sustained virological response to interferon plus ribavirin reduces liver‐related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

  2009cited by this paper
• Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

  2009cited by this paper
• Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

  2008cited by this paper
• Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial

  2008cited by this paper
• Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease.

  2007cited by this paper
• A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study

  2007cited by this paper
• Kaplan-Meier methods yielded misleading results in competing risk scenarios.

  2006cited by this paper
• The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.

  2006cited by this paper
• A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

  2006cited by this paper
• Treating viral hepatitis C: efficacy, side effects, and complications

  2006cited by this paper
• Extrahepatic disease manifestations of HCV infection: some current issues.

  2004cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening.

  2002cited by this paper
• Side effects of therapy of hepatitis C and their management

  2002cited by this paper
• A Proportional Hazards Model for the Subdistribution of a Competing Risk

  1999cited by this paper
• Hepatitis C: A Multifaceted Disease: Review of Extrahepatic Manifestations

  1995cited by this paper
• A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

  1988cited by this paper
• A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

  1987cited by this paper

• Choosing real-world data for clinical and epidemiological research: methodological lessons from NHIRD and TriNetX—A narrative review

  2026cites this paper
• Long-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH).

  2025cites this paper
• Micro-elimination of hepatitis C in patients with chronic kidney disease and diabetes in Taiwan.

  2025cites this paper
• Direct-Acting Antivirals and Risk of Hepatitis C Extrahepatic Manifestations

  2025cites this paper
• Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real‐World Experience From the Nationwide Taiwan Hepatitis C Virus Registry

  2025cites this paper
• Change in Estimated Glomerular Filtration Rate After Direct-Acting Antiviral Treatment in Chronic Hepatitis C Patients

  2025cites this paper
• Causal Mediation Analyses for the Natural Course of Hepatitis C: A Prospective Cohort Study

  2024cites this paper
• Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection With Interferon or Direct Antiviral Therapy

  2024cites this paper
• BLOOD VISCOSITY AND GIT DISORDERS OF HCV PATIENTS

  2024cites this paper
• Association between chronic viral infection‐related hospitalization and risk of cardiovascular disease: A population‐based cohort study

  2024cites this paper
• Association between treatment of hepatitis C virus and risk of cardiovascular disease among insured patients with the virus in the United States

  2023cites this paper
• Bouncing back or slowing down renal function decline after hepatitis C virus eradication

  2023cites this paper
• Hepatitis C treatment and long‐term outcome of patients with hepatocellular carcinoma after resection

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• Cardioprotective effect of antiviral therapy among hepatitis C infected patients: A meta-analysis

  2023cites this paper
• Severe hepatitis B flares with hepatic decompensation after withdrawal of nucleos(t)ide analogues: A population‐based cohort study

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• The possible role of Helicobacter pylori in liver diseases

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• Long-term evolution of estimated glomerular filtration rate in patients with antiviral treatment for hepatitis C virus infection.

  2022cites this paper
• Changes in renal function in patients with chronic hepatitis C treated with sofosbuvir‐velpatasvir

  2022cites this paper
• Heart Failure in Chronic Infectious and Inflammatory Conditions: Mechanistic Insights from Clinical Heterogeneity

  2022cites this paper
• Association between Anti-Hepatitis C Viral Intervention Therapy and Risk of Sjögren’s Syndrome: A National Retrospective Analysis

  2022influential citation
• Increased All-cause Mortality in People With HIV and Comorbidities: Hepatitis B and C Virus Seropositivity and Hyperglycemia in Myanmar, 2005–2017

  2022influential citation
• When and in Whom to Initiate HCV Therapy

  2022cites this paper
• KDIGO 2022 Clinical Practice Guideline FOR the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

  2022cites this paper
• When and in Whom to Initiate HCV Therapy

  2022cites this paper
• Cardiovascular Implications of Immune Disorders in Women

  2022cites this paper
• Hepatitis Virus C-associated Nephropathy: A Review and Update

  2022cites this paper
• Protective effect of interferon-based antiviral therapy on risk of bipolar disorder in patients with hepatitis C Virus infection: A nationwide longitudinal study

  2022cites this paper
• When and in Whom to Initiate HCV Therapy

  2022cites this paper
• Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study

  2022cites this paper
• Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta‐analysis

  2021cites this paper
• Long‐term risk of end‐stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Extrahepatic Manifestations of Chronic HCV Infection.

  2021cites this paper
• B-type natriuretic peptide (BNP) in HCV-positive Egyptian patients: the impact of HCV eradication on plasma BNP levels

  2021cites this paper
• Impact of direct acting antivirals (DAA) on neurologic disorders in chronic hepatitis C.

  2021cites this paper
• The effect of direct acting antiviral agents on vascular endothelial function in Egyptian patients with chronic hepatitis C virus infection

  2021cites this paper
• Renal function trajectories in hepatitis C infection: differences between renal healthy and chronic kidney disease individuals

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Effect of Direct Antiviral Agents on Atherosclerosis in Patients with Chronic Hepatitis C.

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Development of Focal segmental glomerulosclerosis 4- years following direct-acting antiviral therapy for hepatitis C virus infection: Case report

  2021cites this paper
• Hepatitis C Virus Infection and the New Therapeutical Approach

  2021cites this paper
• Cytotoxin‐associated gene A (CagA) promotes aortic endothelial inflammation and accelerates atherosclerosis through the NLRP3/caspase‐1/IL‐1β axis

  2021cites this paper
• A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy

  2021cites this paper
• Sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for treating patients with hepatitis C virus reinfection following direct‐acting antiviral‐induced sustained virologic response

  2021cites this paper
• Extrahepatic Manifestations of Hepatitis C Virus Infection

  2021cites this paper
• Impact of Direct-Acting Antivirals (daas) on cardiovascular diseases in patients with chronic hepatitis C.

  2021cites this paper
• Natural History of Hepatitis C Infection

  2021cites this paper
• Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: a large cohort study from the nationwide HCV Registry Program (TACR).

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• The eGFR Change and Risk Factors in Moderate Chronic Kidney Disease Patients after Successful HCV Clearance by Direct Anti-viral Agents

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Elbasvir and grazoprevir for the treatment of hepatitis C

  2021cites this paper
• Four prescribed Chinese herbal medicines provide renoprotection and survival benefit without hyperkalemia risk in patients with advanced chronic kidney disease: A nationwide cohort study.

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Inflammation, Autoimmunity, Infection, and Stroke

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Validity of ICD-10-CM Codes Used to Identify Patients with Chronic Hepatitis B and C Virus Infection in Administrative Claims Data from the Taiwan National Health Insurance Outpatient Claims Dataset

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• The effectiveness and safety of sofosbuvir‐ledipasvir for patients with hepatitis C virus genotype 2 infection

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review.

  2020cites this paper
• Mixed cryoglobulinemia associated with chronic HCV infection in the era of modern antiviral therapy: Can the problem be considered solved?

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Clinical effects of simvastatin in chronic hepatitis C patients receiving sofosbuvir/daclatasvir combination. A randomized, placebo-controlled, double-blinded study

  2020cites this paper
• Impact of hepatitis C virus treatment on the risk of non‐hepatic cancers among hepatitis C virus‐infected patients in the US

  2020cites this paper
• Sex Differences in Extrahepatic Outcomes After Antiviral Treatment for Hepatitis C.

  2020cites this paper
• Clinical epidemiology of extrahepatic manifestations of chronic hepatitis C virus infection

  2020cites this paper
• Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease.

  2020cites this paper
• Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons.

  2020cites this paper
• Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH)

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Morbid obesity and hepatitis C: treat as normal or are there additional issues to consider?

  2020cites this paper
• Treatment of hepatitis C virus in renal disease: can we use all the drugs without additional monitoring?

  2020cites this paper
• Viral hepatitis in patients on hemodialysis

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations.

  2020cites this paper
• HCV in the haemodialysis population: Treat now or later?

  2020cites this paper
• Direct acting antiviral HCV treatment does not influence renal function

  2020cites this paper
• EFFECTIVENESS OF COMBINATION THERAPY WITH EFFECTIVENESS OF COMBINATION THERAPY WITH SOFOSBUVIR AND DACLATASVIR IN HCV INFECTED PATIENTS SOFOSBUVIR AND DACLATASVIR IN HCV INFECTED PATIENTS

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Infection and atherosclerosis: TLR-dependent pathways

  2020cites this paper
• KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C.

  2020cites this paper
• Validity of ICD-10-CM Codes Used to Identify Patients with Chronic Hepatitis B and C Virus Infection in Administrative Claims Data from the Taiwan National Health Insurance Outpatient Claims Dataset

  2020cites this paper